Enzalutamide (trade name: Xtandi) has been approved since December 2014 for men who have metastatic prostate cancer that is not susceptible to hormone-blocking therapy, who have no symptoms or only mild ones, and in whom chemotherapy is not yet indicated. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.

According to the findings, in comparison with watchful waiting the drug can prolong overall survival and delay the occurrence of disease complications. In men aged 75 years or older, IQWiGsees an indication of a major added benefit. There is also an indication of an added benefit in younger men; however, the extent is rated as “considerable”.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/enzalutamide-indication-of-major-added-benefit-for-over-75-year-olds.6632.html